BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.61 Decreased By ▼ -0.39 (-0.74%)
BOP 34.23 Increased By ▲ 0.24 (0.71%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.23 Increased By ▲ 0.03 (0.25%)
FCCL 53.80 Increased By ▲ 0.97 (1.84%)
FCSC 5.24 Increased By ▲ 0.17 (3.35%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.07 Increased By ▲ 0.05 (0.62%)
KOSM 5.39 Decreased By ▼ -0.13 (-2.36%)
MLCF 87.90 Increased By ▲ 1.39 (1.61%)
NBP 186.60 Increased By ▲ 1.44 (0.78%)
PACE 10.75 Increased By ▲ 0.17 (1.61%)
PAEL 39.95 Increased By ▲ 0.53 (1.34%)
PIAHCLA 26.19 Decreased By ▼ -0.03 (-0.11%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 233.49 Increased By ▲ 5.31 (2.33%)
PRL 34.98 Increased By ▲ 0.30 (0.87%)
PTC 67.71 Increased By ▲ 2.38 (3.64%)
SEARL 90.90 Increased By ▲ 0.77 (0.85%)
SSGC 27.20 Increased By ▲ 0.60 (2.26%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.85 Increased By ▲ 2.35 (4.02%)
TPLP 8.78 Increased By ▲ 0.56 (6.81%)
TREET 24.65 Increased By ▲ 0.12 (0.49%)
TRG 71.50 Increased By ▲ 1.79 (2.57%)
WAVES 10.01 Increased By ▲ 0.07 (0.7%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
اردو
Android App
Print Edition Dollar to PKR
Budget 2026-27 Iran-US war Petrol Prices Gold Rates Podcasts PSX Notices
World

Pfizer and BioNTech request EU to approve vaccine for 12 to 15 year olds

  • Pfizer and BioNTech will be seeking approval from the European Medicines Agency (EMA) to approve their coronavirus vaccine for use on 12-15 year olds.
  • The companies articulated that the children will continue to be monitored for longer-term protection and safety for an additional two years.
Published April 30, 2021 Updated April 30, 2021 05:19pm
Save
1 min
comment
By BR Web Desk
Add BRecorder as a trusted
source on Google
Google Preferred Source

Pfizer-BioNTech will be seeking approval from the European Medicines Agency (EMA) to approve their coronavirus vaccine for use on 12-15 year olds.

In a statement on Friday, the two companies stated that their submission to the European Medicines Agency was based on an advanced study in over 2000 adolescents, which showed that the vaccine was safe and effective.

The companies articulated that the children will continue to be monitored for longer-term protection and safety for an additional two years.

Reportedly, this move could offer younger and less at-risk populations in Europe access to the vaccines for the first time, as the shot is based on novel mRNA technology.

BioNTech Pfizer COVID19 European Medicines Agency

Comments

Comments are closed for this article.

More Stories

Browse all stories